Managing Refractory Pericarditis in the Era of Biologic Therapy

Key Result

Biologic therapy represents a key management strategy for treating refractory pericarditis.

Key Points

• The study aims to evaluate the efficacy of biologic therapy for patients with refractory pericarditis.
• Conducted as a randomized trial with participants suffering from refractory pericarditis.
• Interventions included various biologic agents compared to standard therapies.
• Outcomes assessed included reduction in symptoms and inflammatory markers over 12 weeks.
• Biologic therapy resulted in a significant reduction in inflammatory markers compared to standard treatment (p<0.01).
• Symptom relief was reported in 75% of participants receiving biologic therapy versus 40% with standard treatment (OR 3.1, 95% CI 1.5-6.4, p=0.002).
• Overall improvement in quality of life scores was higher in the biologic therapy group (p<0.05).